These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 35611186)
1. James CA; Ronning P; Cullinan D; Cotto KC; Barnell EK; Campbell KM; Skidmore ZL; Sanford DE; Goedegebuure SP; Gillanders WE; Griffith OL; Hawkins WG; Griffith M Cancer Res Commun; 2021 Nov; 1(2):115-126. PubMed ID: 35611186 [TBL] [Abstract][Full Text] [Related]
2. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919 [TBL] [Abstract][Full Text] [Related]
3. Advances in personalized neoantigen vaccines for cancer immunotherapy. Sun C; Xu S Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF. Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM Front Immunol; 2020; 11():1147. PubMed ID: 32582212 [TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
6. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]
7. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174 [TBL] [Abstract][Full Text] [Related]
8. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. Roesler AS; Anderson KS Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074 [TBL] [Abstract][Full Text] [Related]
9. HLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design. Hu W; He M; Li L PLoS One; 2020; 15(2):e0229327. PubMed ID: 32106223 [TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design. Xin K; Wei X; Shao J; Chen F; Liu Q; Liu B Hum Vaccin Immunother; 2024 Dec; 20(1):2300881. PubMed ID: 38214336 [TBL] [Abstract][Full Text] [Related]
11. Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans. Fritsch EF; Ott PA Cancer Res; 2024 Apr; 84(7):953-955. PubMed ID: 38558128 [TBL] [Abstract][Full Text] [Related]
12. Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion? Manoutcharian K; Guzman Valle J; Gevorkian G Arch Immunol Ther Exp (Warsz); 2021 Apr; 69(1):12. PubMed ID: 33909124 [TBL] [Abstract][Full Text] [Related]
13. [Cancer Vaccine Focused on Neoantigens]. Shindo Y; Hazama S; Nagano H Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772 [TBL] [Abstract][Full Text] [Related]